Combined treatment of LEE011 and ruxolitinib synergistically inhibit NKTCL cell growth, suggesting that targeting of both CDK4/6 and JAK1/2 are promising treatment alternatives for NKTCL [67]. Here, JAK1 is linked to extranodal nasal NK/T cell lymphoma.